Literature DB >> 29437867

Evidence for genetic anticipation in vonHippel-Lindau syndrome.

M Stephen Meyn1,2,3,4, Harriet Druker5,3,6, Laura Aronoff5,7, David Malkin5,1,2,8, Kalene van Engelen1, Bailey Gallinger5,1,3,6, Jonathan Wasserman1,2,9, Raymond H Kim4,10,11, Anita Villani5,2.   

Abstract

BACKGROUND: von Hippel-Lindau (vHL) syndrome is a rare autosomal-dominant disorder that confers a lifelong risk for developing both benign and malignant tumours in multiple organs. Recent evidence suggests that vHL may exhibit genetic anticipation (GA). The aim of this study was to determine if GA occurs in vHL, and if telomere shortening may be a factor in GA.
METHODS: A retrospective chart review of vHL families seen at The Hospital for Sick Children between 1984 and 2016 was performed. Age of onset (AOO, defined as the age of first physician-diagnosed vHL-related manifestation) was confirmed for 96 patients from 20 unrelated families (80 clinically affected and 16 unaffected carriers). Flow-FISH(flow cytometry sorting of cells whose telomeres are labeled by Fluorescence In Situ Hybridization) was used to measure mean telomere length of six white blood cell subtypes from 14 known VHL pathogenic variant carriers.
RESULTS: The median AOO for generations I, II and III were 32.5, 22.5 and 12.0 years, respectively. The differences in the AOO between generations were highly significant using a Cox proportional hazards model (P=6.00×10-12). Telomere lengths were significantly different for granulocytes and natural killer lymphocytes of patients with vHL compared with age-matched controls. For six vHL parent-child pairs, median white blood cell telomere lengths between parent and child were not significantly different.
CONCLUSIONS: Our results suggest that vHL telomere abnormalities may be primarily somatic in origin rather than a cause of GA. As tumour development exhibits GA in our cohort, vHL surveillance guidelines may need to account for a patient's generational position within a vHL pedigree. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  anticipation; cancer predisposition; surveillance; telomeres; von Hippel-Lindau

Mesh:

Substances:

Year:  2018        PMID: 29437867     DOI: 10.1136/jmedgenet-2017-104882

Source DB:  PubMed          Journal:  J Med Genet        ISSN: 0022-2593            Impact factor:   6.318


  3 in total

1.  Large scale genotype- and phenotype-driven machine learning in Von Hippel-Lindau disease.

Authors:  Andreea Chiorean; Kirsten M Farncombe; Sean Delong; Veronica Andric; Safa Ansar; Clarissa Chan; Kaitlin Clark; Arpad M Danos; Yizhuo Gao; Rachel H Giles; Anna Goldenberg; Payal Jani; Kilannin Krysiak; Lynzey Kujan; Samantha Macpherson; Eamonn R Maher; Liam G McCoy; Yasser Salama; Jason Saliba; Lana Sheta; Malachi Griffith; Obi L Griffith; Lauren Erdman; Arun Ramani; Raymond H Kim
Journal:  Hum Mutat       Date:  2022-05-10       Impact factor: 4.700

2.  Biological and clinical impact of central nervous system hemangioblastomas in Chinese patients with von Hippel-Lindau disease: implications for treatment.

Authors:  Liang Li; Zhiqiang Yi; Zhen Liu; Hongzhou Duan; Runchun Lu; Chunwei Li; Lei Li; Kan Gong
Journal:  Hered Cancer Clin Pract       Date:  2020-10-22       Impact factor: 2.857

3.  Intra-Familial Phenotypic Heterogeneity and Telomere Abnormality in von Hippel- Lindau Disease: Implications for Personalized Surveillance Plan and Pathogenesis of VHL-Associated Tumors.

Authors:  Jiangyi Wang; Xiang Peng; Cen Chen; Xianghui Ning; Shuanghe Peng; Teng Li; Shengjie Liu; Baoan Hong; Jingcheng Zhou; Kaifang Ma; Lin Cai; Kan Gong
Journal:  Front Genet       Date:  2019-04-24       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.